MK0653, ezetimibe + Comparator: placebo
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Lipid Metabolism, Inborn Errors
Conditions
Lipid Metabolism, Inborn Errors, Heart Disease
Trial Timeline
Feb 12, 2001 → Nov 30, 2004
NCT ID
NCT00092820About MK0653, ezetimibe + Comparator: placebo
MK0653, ezetimibe + Comparator: placebo is a phase 3 stage product being developed by Organon for Lipid Metabolism, Inborn Errors. The current trial status is completed. This product is registered under clinical trial identifier NCT00092820. Target conditions include Lipid Metabolism, Inborn Errors, Heart Disease.
What happened to similar drugs?
20 of 20 similar drugs in Lipid Metabolism, Inborn Errors were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00092898 | Phase 3 | Completed |
| NCT00092807 | Phase 3 | Completed |
| NCT00092820 | Phase 3 | Completed |
Competing Products
20 competing products in Lipid Metabolism, Inborn Errors